Injecto Polymers IPO Overview
Injecto Polymers IPO is a BSE SME public issue worth ₹56.12 crore. The IPO opened for subscription on September 11, 2026, and will close on September 16, 2026. The price band is fixed at ₹98 to ₹100 per share, with a lot size of 1,200 shares.
The company operates in the flexible and industrial plastic packaging segment and manufactures products used by customers across several industries.
| Particular | Details |
|---|---|
| IPO Name | Injecto Polymers IPO |
| IPO Type | BSE SME |
| IPO Dates | Sep 11–16, 2026 |
| Price Band | ₹98–₹100 |
| Issue Size | ₹56.12 Cr |
| Lot Size | 1,200 Shares |
| Min. Investment | ₹1.20 Lakh |
| Allotment | Sep 17, 2026 |
| Refund / Demat | Sep 18, 2026 |
| Listing Date | Sep 21, 2026 |
| Listing Exchange | BSE SME |
| Lead Manager | Indcap Advisors |
At the upper price band of ₹100, one lot requires an investment of ₹1.20 lakh. The IPO is being marketed as an SME offering with fresh capital intended to support expansion and financial requirements.
Injecto Polymers IPO GMP Today
The latest available GMP indications show ₹0, meaning there is currently no meaningful grey-market premium being reported. One tracker also showed the GMP at ₹0 around the IPO opening period.
At a GMP of ₹0 and an upper issue price of ₹100, the indicative GMP-based price remains around ₹100.
GMP is unofficial and unregulated, so investors should not consider it a guaranteed indication of the actual listing price. The premium can change significantly before listing.
Injecto Polymers IPO Subscription
Injecto Polymers IPO opened on September 11 and will remain available for bidding until September 16. The issue is one of the SME offerings attracting attention alongside Century Business Media during the current IPO cycle.
Investors should monitor the final category-wise subscription figures, particularly QIB, NII and retail demand, before the issue closes. Subscription data can change substantially on the final bidding day.
Injecto Polymers Business
Injecto Polymers operates in the plastic packaging and polymer products industry. Its product portfolio includes PP woven fabrics and bags, BOPP bags, Leno bags, LDPE and polyester pouches, FIBC products, non-woven products and plastic granules and PVC resins.
The company's products are used across different industrial and packaging applications. Its manufacturing operations are located in West Bengal, providing an established base for serving customers in its primary market.
The diversified product range allows the company to participate in multiple packaging categories rather than depending on a single product line.
Injecto Polymers Financial Performance
Injecto Polymers has recorded strong revenue growth over the recent financial years.
| Financial Year | Revenue | PAT |
|---|---|---|
| FY24 | ₹109.80 Cr | ₹4.44 Cr |
| FY25 | ₹261.85 Cr | ₹8.11 Cr |
| FY26 | ₹375.83 Cr | ₹16.01 Cr |
Revenue increased substantially from around ₹109.80 crore in FY24 to approximately ₹375.83 crore in FY26. PAT also increased from ₹4.44 crore to around ₹16.01 crore during the same period.
The company reported FY26 EBITDA of approximately ₹38.04 crore, indicating a significant improvement in operating scale. However, investors should also consider the company's relatively high debt and working-capital requirements while evaluating the earnings growth.
Injecto Polymers IPO Financial Ratios
Based on the reported FY26 financial performance, the company had several notable profitability and valuation metrics.
| Particular | FY26 |
|---|---|
| EPS | ₹10.55 |
| EBITDA Margin | 10.13% |
| PAT Margin | 4.26% |
| RoNW | 41.73% |
| ROCE | 15.64% |
| Debt/Equity | 2.61 |
| NAV | ₹41.67 |
The strong RoNW and revenue growth are positives, but the 2.61 debt-to-equity ratio is an important factor to watch. A significant portion of the company's growth needs to be evaluated alongside its borrowing and working-capital requirements.
Injecto Polymers IPO Objectives
The IPO proceeds are primarily intended for capacity expansion and debt-related requirements.
A major portion of the funds is planned for Phase IV capital expenditure at the company's existing manufacturing facility. The company also intends to use part of the proceeds for repayment of borrowings, with the remaining funds allocated toward general corporate purposes.
The planned expansion could help Injecto Polymers increase production capacity and cater to higher demand if the company's existing growth trend continues.
Injecto Polymers IPO Strengths
Injecto Polymers has several positive factors in its IPO story:
- Strong revenue growth between FY24 and FY26.
- PAT increased significantly over the same period.
- Diversified plastic packaging product portfolio.
- Exposure to multiple industrial end-use sectors.
- Planned capacity expansion through IPO proceeds.
- Part of the funds will be used for debt reduction.
- Strong FY26 RoNW of around 41.73%.
Injecto Polymers IPO Risks
The plastic packaging industry is highly competitive and sensitive to raw-material prices. Changes in polymer prices can directly affect production costs and operating margins.
The company also has significant borrowings, making its 2.61 debt-to-equity ratio an important risk factor. Working-capital requirements can further increase the company's dependence on external funding.
Another concern is geographic concentration. A substantial portion of the company's sales comes from West Bengal, which could expose it to regional demand and customer-concentration risks.
Environmental regulations, competition from alternative packaging materials and changes in industrial demand could also affect future growth.
Injecto Polymers IPO Valuation
At the upper price band of ₹100, the IPO valuation should be assessed against the company's FY26 earnings and strong recent revenue growth.
The company's FY26 EPS of around ₹10.55 gives the issue an attractive-looking earnings profile at first glance. However, investors should balance this against the company's debt, working-capital intensity and competitive industry.
The current ₹0 GMP does not provide a positive grey-market premium signal. Therefore, the fundamental financial performance and valuation become even more important for investors considering the issue.
Injecto Polymers IPO Review
Injecto Polymers IPO presents a mixed-to-positive fundamental story. The company has delivered substantial revenue and profit growth, while its diversified packaging portfolio and planned capacity expansion provide potential for further growth.
The main concerns are leverage, working-capital requirements, raw-material price volatility and competition. The absence of a meaningful GMP also means investors currently have limited grey-market support for a potential listing premium.
For investors comfortable with SME stocks and manufacturing-sector risks, the IPO can be evaluated based on its growth and valuation. More conservative investors may prefer to wait for stronger subscription demand and clearer market sentiment.
Injecto Polymers IPO Key Highlights
- IPO Size: ₹56.12 crore
- Price Band: ₹98–₹100
- Lot Size: 1,200 shares
- Minimum Investment: ₹1.20 lakh
- IPO Closing: September 16, 2026
- Allotment: September 17, 2026
- Refund/Demat: September 18, 2026
- Listing: September 21, 2026
- Latest GMP: ₹0
- IPO Type: BSE SME
- FY26 Revenue: ₹375.83 crore
- FY26 PAT: ₹16.01 crore
- FY26 EBITDA: ₹38.04 crore
- FY26 Debt/Equity: 2.61
Injecto Polymers IPO Conclusion
Injecto Polymers IPO offers exposure to a growing plastic packaging manufacturer with significant revenue and profit improvement over the last three financial years. Its diversified product portfolio and planned manufacturing expansion are important positives.
However, investors should pay close attention to the company's leverage, working-capital requirements, raw-material costs and competitive environment. The current GMP of ₹0 also indicates that there is no clear grey-market premium signal at present.
Overall, Injecto Polymers IPO can be considered by investors who understand SME and manufacturing-sector risks, but valuation, debt levels and final subscription demand should be assessed carefully before applying.
Disclaimer: IPO GMP is unofficial and can change rapidly. Investors should review the company's offer documents, financial statements, valuation and risk factors before making an investment decision.
Loading comments...